Cost Curve
everything drug pricing and policy, every day
Connect
And yesterday’s earnings calls included a lot of fascinating policy commentary from pharma CEOs
Plus a roundup of reactions to the Trump executive order, one week later
And going back to the United earnings call for some verbatims about the state of PBMs
Plus a new LinkedIn video, two great newsletter editions, and a fantastic “alternative funding program” link to check out
And it feels like we’re overdue for some deeper IRA conversations ... but we can punt that to next week
And looking at the drug-pricing executive order from even more angles
I really thought today might be an easy day. I should have known better.
And PBM divestment of pharmacies is so hot right now (and yes, one tariff link)
And the hospital lobby tries to pump up the argument that it’s investing in charity care
And ‘middlemen’ take a beating from PhRMA’s ads, Arkansas’ legislation
And the best comments from the oral argument in Novo’s IRA appeal
And I wish there was something more nuanced to say than ‘pharma tariffs are dumb,’ but ... tariffs are dumb
